Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
University of Nebraska
UNC Lineberger Comprehensive Cancer Center
Spanish Breast Cancer Research Group
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
City of Hope Medical Center
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
University of Wisconsin, Madison
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Wake Forest University Health Sciences
Dana-Farber Cancer Institute
NRG Oncology
University of Michigan Rogel Cancer Center
University of Wisconsin, Madison
Rutgers, The State University of New Jersey
Mayo Clinic
Ottawa Hospital Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mayo Clinic
Massachusetts General Hospital
University of Nebraska
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of Kentucky
Nationwide Children's Hospital
Duke University
NRG Oncology
Dana-Farber Cancer Institute
City of Hope Medical Center
Virginia Commonwealth University
Ohio State University Comprehensive Cancer Center
University of California, San Diego
Ohio State University Comprehensive Cancer Center
University of Kentucky
University of Texas Southwestern Medical Center
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Mayo Clinic
Universitaire Ziekenhuizen KU Leuven
M.D. Anderson Cancer Center
SOLTI Breast Cancer Research Group
NRG Oncology
University of Michigan Rogel Cancer Center
University of Chicago
Samsung Medical Center
University of Chicago
Thomas Jefferson University
Thomas Jefferson University
Washington University School of Medicine